173 related articles for article (PubMed ID: 34940080)
1. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
Patel YP; Husereau D; Leighl NB; Melosky B; Nam J
Curr Oncol; 2021 Dec; 28(6):5278-5294. PubMed ID: 34940080
[TBL] [Abstract][Full Text] [Related]
2. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
Harvey MJ; Cunningham R; Sawchyn B; Montesion M; Reddy P; McBride A; Chawla AJ
JCO Precis Oncol; 2021 Nov; 5():1611-1624. PubMed ID: 34994647
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact.
Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
Curr Oncol; 2020 Dec; 27(6):e569-e577. PubMed ID: 33380872
[TBL] [Abstract][Full Text] [Related]
4. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
5. Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment.
Russo A; Lee JK; Pasquina LW; Del Re M; Dilks HH; Murugesan K; Madison RW; Lee Y; Schrock AB; Comment L; Dietrich M; Oxnard GR; Rolfo C
JCO Precis Oncol; 2024 Jan; 8():e2300535. PubMed ID: 38295321
[TBL] [Abstract][Full Text] [Related]
6. Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan.
Tsai YL; Chang CJ
Value Health Reg Issues; 2023 May; 35():48-56. PubMed ID: 36863067
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
[TBL] [Abstract][Full Text] [Related]
8. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.
Perdrizet K; Stockley TL; Law JH; Smith A; Zhang T; Fernandes R; Shabir M; Sabatini P; Youssef NA; Ishu C; Li JJ; Tsao MS; Pal P; Cabanero M; Schwock J; Ko HM; Boerner S; Ruff H; Shepherd FA; Bradbury PA; Liu G; Sacher AG; Leighl NB
Cancer Treat Res Commun; 2022; 31():100534. PubMed ID: 35278845
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
[TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
[TBL] [Abstract][Full Text] [Related]
12. Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns.
Israel MA; Danziger N; McGregor KA; Murugesan K; Gjoerup O; Sokol ES; Tukachinsky H; Kurzrock R; Kato S; Sicklick JK; Nimeiri HS; Oxnard GR; Ross JS
Oncologist; 2021 Sep; 26(9):787-796. PubMed ID: 34080753
[TBL] [Abstract][Full Text] [Related]
13. Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.
Matsuda H; Ogawa T; Sadatsuki Y; Tsujino T; Wada S; Kim SW; Hatanaka Y
Respir Investig; 2023 Jan; 61(1):61-73. PubMed ID: 36460584
[TBL] [Abstract][Full Text] [Related]
14. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
[TBL] [Abstract][Full Text] [Related]
15. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB
Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell Lung Cancer for the Colombian Health System.
Gamboa O; Bonilla CE; Quitian D; Torres GF; Buitrago G; Cardona AF
Value Health Reg Issues; 2024 Jan; 39():115-125. PubMed ID: 38101152
[TBL] [Abstract][Full Text] [Related]
18. Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC).
Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
J Med Econ; 2020 Oct; 23(10):1123-1129. PubMed ID: 32597288
[TBL] [Abstract][Full Text] [Related]
19. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
20. Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.
Sheffield BS; Eaton K; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L; Stevens AL; Ewara EM; Cheema P
Curr Oncol; 2023 Feb; 30(2):2348-2365. PubMed ID: 36826141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
